You are here

  • Home
  • Online First
  • A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes

Article Text

Article menu

other Versions

Download PDFPDF
Neurodegeneration
Research paper
A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes
  1. N K Magdalinou1,
  2. R W Paterson2,
  3. J M Schott2,
  4. N C Fox2,
  5. C Mummery2,
  6. K Blennow3,
  7. K Bhatia4,
  8. H R Morris5,
  9. P Giunti6,
  10. T T Warner1,
  11. R de Silva1,
  12. A J Lees1,
  13. H Zetterberg4,6
  1. 1Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, UK
  2. 2Department of Neurodegeneration, Dementia Research Centre, UCL Institute of Neurology, London, UK
  3. 3Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
  4. 4Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, London, UK
  5. 5Department of Clinical Neuroscience, UCL Institute of Neurology, Royal Free Hospital, London, UK
  6. 6Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
  1. Correspondence to Dr Nadia Magdalinou, Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, 1 Wakefiled Street, London WC1N 1PJ, UK; n.magdalinou{at}ucl.ac.uk

Abstract

Background Patients presenting with parkinsonian syndromes share many clinical features, which can make diagnosis difficult. This is important as atypical parkinsonian syndromes (APSs) such as progressive supranuclear palsy (PSP), multiple system atrophy (MSA) and corticobasal syndrome (CBS) carry a poor prognosis, compared with patients with Parkinson's disease (PD). In addition, there is overlap between APS and dementia diseases, such as Alzheimer's disease (AD) and frontotemporal dementia (FTD).

Objective To use a panel of cerebrospinal fluid (CSF) biomarkers to differentiate patients with APS from PD and dementia.

Methods A prospective cohort of 160 patients and 30 control participants were recruited from a single specialist centre. Patients were clinically diagnosed according to current consensus criteria. CSF samples were obtained from patients with clinical diagnoses of PD (n=31), PSP (n=33), CBS (n=14), MSA (n=31), AD (n=26) and FTD (n=16). Healthy, elderly participants (n=30) were included as controls. Total τ (t-τ), phosphorylated τ (p-τ), β-amyloid 1–42 (Aβ42), neurofilament light chain (NFL), α-synuclein (α-syn), amyloid precursor protein soluble metabolites α and β (soluble amyloid precursor protein (sAPP)α, sAPPβ) and two neuroinflammatory markers (monocyte chemoattractant protein-1 and YKL-40) were measured in CSF. A reverse stepwise regression analysis and the false discovery rate procedure were used.

Results CSF NFL (p<0.001), sAPPα (p<0.001) and a-syn (p=0.003) independently predicted diagnosis of PD versus APS. Together, these nine biomarkers could differentiate patients with PD from APS with an area under the curve of 0.95 and subtypes of APS from one another. There was good discriminatory power between parkinsonian groups, dementia disorders and healthy controls.

Conclusions A panel of nine CSF biomarkers was able to differentiate APS from patients with PD and dementia. This may have important clinical utility in improving diagnostic accuracy, allowing better prognostication and earlier access to potential disease-modifying therapies.

  • CSF
  • PARKINSON'S DISEASE
  • CORTICOBASAL DEGENERATION
  • SUPRANUCLEAR PALSY
  • POST MORTEM

https://doi.org/10.1136/jnnp-2014-309562

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text